{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:52:54Z","timestamp":1761897174884,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008750","name":"Shanghai Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC12017129"],"award-info":[{"award-number":["SHDC12017129"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.81871276"],"award-info":[{"award-number":["No.81871276"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Adamantiades-Beh\u00e7et\u2019s Disease (ABD) is an immunological recurrent systemic vasculitis with a chronic course. We investigated the predictors of long-term flare-ups, poor outcomes and event-free survival in Chinese non-surgical patients with intestinal ABD.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This was a prospective cohort study of 109 intestinal ABD patients seen in our institution between October 2012 and January 2019 who met the international criteria for ABD and had intestinal ulcers confirmed on colonoscopy. Predictors of relapses and poor outcomes, event-free survival were calculated using logistic regression models and Cox proportional hazard regression models, respectively.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Sixty-six intestinal ABD patients (60.55%) had ileocecal ulcers; 19 patients (17.43%) presented with colorectum ulcers; 24 patients (22.02%) showed both ileocecal and colorectum ulcers. 7 patients (6.42%) experienced at least 1 flare-up of intestinal ulcers. 38 patients (34.86%) complained of non-healing intestinal ulcers. In multivariate analysis, location of intestinal ulcers (ileocecal and colorectum) (odd ratio (OR) 7.498 [95% confidence interval [95% CI] 1.844\u201330.480]), erythrocyte sedimentation rate (ESR) &gt;\u200924\u2009mm\/h (OR 5.966 [95% CI 1.734\u201320.528]), treatment with infliximab (IFX) (OR 0.130 [95% CI 0.024\u20130.715]), and poor compliance (OR 11.730 [95% CI 2.341\u201358.781]) were independently correlated with a poor outcome. After a median follow-up of 28\u2009months, 45 intestinal ABD patients (41.28%) underwent adverse events. Factors independently associated with shorter event-free survival were early onset of ABD (&lt;\u20097\u2009years) (hazard ratio (HR) 2.431 [95% CI 1.240\u20134.764]) and poor compliance (HR 3.058 [95% CI 1.612\u20135.800]).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Distribution of intestinal ulcers (ileocecal and colorectum), ESR &gt;\u200924\u2009mm\/h, treatment without IFX, and poor compliance were independent risk factors for poor outcomes in non-surgical intestinal ABD patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13023-019-1228-9","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T16:02:47Z","timestamp":1574956967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Poor prognostic factors in patients with newly diagnosed intestinal Adamantiades-Beh\u00e7et\u2019s disease in the Shanghai Adamantiades-Beh\u00e7et\u2019s disease database: a prospective cohort study"],"prefix":"10.1186","volume":"14","author":[{"given":"Liang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Fen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Hong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6481-480X","authenticated-orcid":false,"given":"Jian-Long","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,28]]},"reference":[{"key":"1228_CR1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/BOR.0b013e3282f154d1","volume":"20","author":"I Krause","year":"2008","unstructured":"Krause I, Weinberger A. Behcet\u2019s disease. Curr Opin Rheumatol. 2008;20:82\u20137.","journal-title":"Curr Opin Rheumatol"},{"key":"1228_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/BOR.0000000000000349","volume":"29","author":"P Leccese","year":"2016","unstructured":"Leccese P, Yazici Y, Olivieri I. Behcet's syndrome in nonendemic regions. Curr Opin Rheumatol. 2016;29:12\u20136.","journal-title":"Curr Opin Rheumatol"},{"key":"1228_CR3","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1093\/rheumatology\/kex285","volume":"56","author":"T Ishido","year":"2017","unstructured":"Ishido T, Horita N, Takeuchi M, KawagoeT SE, Yamane T. Clinical manifestations of Behcet\u2019s disease depending on sex and age: results from Japanese nationwide registration. Rheumatology. 2017;56:1918\u201327.","journal-title":"Rheumatology."},{"key":"1228_CR4","first-page":"1078","volume":"335","author":"International Study Group for Behcet\u2019s Disease","year":"1990","unstructured":"International Study Group for Behcet\u2019s Disease. Criteria for diagnosis of Behcet\u2019s disease. Lancet. 1990;335:1078\u201380.","journal-title":"Lancet."},{"key":"1228_CR5","first-page":"920","volume":"52","author":"YS Jung","year":"2017","unstructured":"Jung YS, Han M, Kim WH, Cheon JH, Park S. Incidence and clinical outcomes of inflammatory bowel disease in South Korea, 2011\u20132014: a Nationwide population-based study. Digest Dis Sci. 2017;52:920\u20138.","journal-title":"Digest Dis Sci"},{"key":"1228_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/ibd.22991","volume":"19","author":"YS Jung","year":"2013","unstructured":"Jung YS, Cheon JH, Park SJ, Hong SP, Kim TI, Kim WH. Long-term clinical outcomes of Crohn's disease and intestinal Behcet's disease. Inflamm Bowel Dis. 2013;19:99\u2013105.","journal-title":"Inflamm Bowel Dis"},{"key":"1228_CR7","first-page":"488","volume":"150","author":"CC Zouboulis","year":"1999","unstructured":"Zouboulis CC. Epidemiology of Adamantiades-Beh\u00e7et's disease. Ann Med Interne. 1999;150:488\u201398.","journal-title":"Ann Med Interne"},{"key":"1228_CR8","first-page":"1","volume":"16","author":"TI Kim","year":"2001","unstructured":"Kim TI, Kim WH, Lee JH, Lee CR, Kang JK, Kim NK, et al. Clinical course and relapse rate in intestinal Behcet's disease. J Gastroen Hepatol. 2001;16:1.","journal-title":"J Gastroen Hepatol"},{"key":"1228_CR9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10620-008-0337-4","volume":"54","author":"CE Ebert","year":"2009","unstructured":"Ebert CE. Gastrointestinal manifestations of Behcet\u2019s disease. Digest Dis Sci. 2009;54:201\u20137.","journal-title":"Digest Dis Sci."},{"key":"1228_CR10","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00384-016-2728-x","volume":"32","author":"J Park","year":"2017","unstructured":"Park J, Cheon JH, Park YE, Lee JY, Lee HJ, Park SJ, et al. Risk factors and outcomes of acute lower gastrointestinal bleeding in intestinal Behcet\u2019s disease. Int J Color Dis. 2017;32:745\u201351.","journal-title":"Int J Color Dis"},{"key":"1228_CR11","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s10620-012-2351-9","volume":"58","author":"YS Jung","year":"2013","unstructured":"Jung YS, Cheon JH, Park SJ, Hong SP, Kim TI, Kim WH. Clinical course of intestinal Behcet's disease during the first five years. Digest Dis Sci. 2013;58:496\u2013503.","journal-title":"Digest Dis Sci."},{"key":"1228_CR12","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/ibd.21313","volume":"17","author":"JH Cheon","year":"2011","unstructured":"Cheon JH, Han DS, Park JY, Ye BD, Jung SA, Hong SP, Park YS, et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Beh\u00e7et's disease. Inflamm Bowel Dis. 2011;17:605\u201313.","journal-title":"Inflamm Bowel Dis"},{"key":"1228_CR13","doi-asserted-by":"publisher","first-page":"17171","DOI":"10.3748\/wjg.v20.i45.17171","volume":"20","author":"J Zou","year":"2014","unstructured":"Zou J, Shen Y, Ji DN, Zheng SB, Guan JL. Endoscopic findings of gastrointestinal involvement in Chinese patients with Behcet's disease. World J Gastroentero. 2014;20:17171\u20138.","journal-title":"World J Gastroentero"},{"key":"1228_CR14","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.1111\/jgh.13598","volume":"32","author":"DH Kim","year":"2017","unstructured":"Kim DH, Park Y, Kim B, Kim WS, Park JS, Hong PS, et al. Fecal calprotectin as a non-invasive biomarker for intestinal involvement of Behcet\u2019s disease. J Gastroen Hepatol. 2017;32:S128\u20139.","journal-title":"J Gastroen Hepatol."},{"key":"1228_CR15","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s10067-018-4344-3","volume":"38","author":"HS Zayed","year":"2019","unstructured":"Zayed HS, Medhat BM, Seif EM. Evaluation of treatment adherence in patients with Behcet\u2019s disease: its relation to disease manifestations, patients\u2019 beliefs about medications, and quality of life. Clin Rheumatol. 2019;38:761\u20138.","journal-title":"Clin Rheumatol"},{"key":"1228_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/(SICI)1097-0258(19980215)17:3<251::AID-SIM762>3.0.CO;2-A","volume":"17","author":"J Urquhart","year":"1998","unstructured":"Urquhart J, Klerk ED. Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens. Stat Med. 1998;17:251\u201367.","journal-title":"Stat Med"},{"key":"1228_CR17","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00384-016-2743-y","volume":"32","author":"YE Park","year":"2017","unstructured":"Park YE, Cheon JH, Park J, Lee JH, Lee HJ, Park SJ, et al. The outcomes and risk factors of early reoperation after initial intestinal resective surgery in patients with intestinal Behcet\u2019s disease. Int J Color Dis. 2017;32:591\u20134.","journal-title":"Int J Color Dis"},{"key":"1228_CR18","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1007\/s10067-017-3904-2","volume":"37","author":"YE Park","year":"2018","unstructured":"Park YE, Cheon JH, Park Y, Park SJ, Kim TI, Kim WH. The outcomes and risk factors of early readmission in patients with intestinal Behcet\u2019s disease. Clin Rheumatol. 2018;37:1913\u201320.","journal-title":"Clin Rheumatol"},{"key":"1228_CR19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00464-015-4166-1","volume":"30","author":"SJ Baek","year":"2016","unstructured":"Baek SJ, Baik SH, Kim WC, Cho MS, Jang HA, Hur H, et al. Short- and long-term outcomes of laparoscopic surgery for intestinal Behcet\u2019s disease: a comparative study with open surgery. Surg Endosc. 2016;30:99\u2013105.","journal-title":"Surg Endosc"},{"key":"1228_CR20","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s10620-014-3198-z","volume":"59","author":"SM Yim","year":"2014","unstructured":"Yim SM, Kim DH, Lee HJ, Jang HW, Park SJ, Hong SP, et al. Mucosal healing predicts the long-term prognosis of intestinal Behcet\u2019s disease. Digest Dis Sci. 2014;59:2529\u201335.","journal-title":"Digest Dis Sci."},{"key":"1228_CR21","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/ibd.21757","volume":"18","author":"YS Jang","year":"2012","unstructured":"Jang YS, Cheon JH, Hong SP, Kim TI, Kim WH. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet's disease. Inflamm Bowel Dis. 2012;18:750\u20137.","journal-title":"Inflamm Bowel Dis"},{"key":"1228_CR22","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1002\/ibd.21517","volume":"17","author":"YS Jung","year":"2011","unstructured":"Jung YS, Yoon JY, Lee JH, Jeon SM, Hong SP, Kim TI, et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet\u2019s disease. Inflamm Bowel Dis. 2011;17:1594\u2013602.","journal-title":"Inflamm Bowel Dis"},{"key":"1228_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/anr.1790020313","volume":"2","author":"MA Rapoff","year":"1989","unstructured":"Rapoff MA. Compliance with treatment regimens for pediatric rheumatic diseases. Arthrit Care Res. 1989;2:40\u20137.","journal-title":"Arthrit Care Res"},{"key":"1228_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/art.1780330105","volume":"33","author":"JD Reveille","year":"1990","unstructured":"Reveille JD, Bartolucci A, Alarc\u00f3n GS. Prognosis in systemic lupus erythematosus. Arthritis Rheum. 1990;33:37\u201348.","journal-title":"Arthritis Rheum"},{"key":"1228_CR25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.5051\/jpis.2019.49.2.76","volume":"49","author":"JB Lee","year":"2019","unstructured":"Lee JB, Shin HJ, Kim DY, Pang EK. Evaluation of prognosis related to compliance with supportive periodontal treatment in patients with chronic periodontitis: a clinical retrospective study. J Periodontal Implant. 2019;49:76\u201389.","journal-title":"J Periodontal Implant"},{"key":"1228_CR26","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1093\/rheumatology\/key033","volume":"57","author":"WL Ng","year":"2018","unstructured":"Ng WL, Adeeb F, Sebastian A, Anjum A, Brady M, Gillespie M, et al. The effects of Behcet\u2019s disease flare-ups on mood: the Midwest of Ireland study. Rheumatology. 2018;57:1124\u201330.","journal-title":"Rheumatology."},{"issue":"4","key":"1228_CR27","doi-asserted-by":"publisher","first-page":"960","DOI":"10.3349\/ymj.2014.55.4.960","volume":"55","author":"HJ Lee","year":"2014","unstructured":"Lee HJ, Shin HS, Jang HW, Kim SW, Park SJ, Hong SP, et al. Correlation between soluble triggering receptor expressed on myeloid Cells-1 and endoscopic activity in intestinal Behcet\u2019s disease. Yonsei Med J. 2014;55(4):960\u20136.","journal-title":"Yonsei Med J"},{"key":"1228_CR28","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1002\/ibd.21600","volume":"17","author":"YS Jung","year":"2011","unstructured":"Jung YS, Kim SW, Yoon JY, Lee JH, Jeon SM, Hong SP, et al. Expression of a soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) correlates with clinical disease activity in intestinal Behcet\u2019s disease. Inflamm Bowel Dis. 2011;17:2130\u20137.","journal-title":"Inflamm Bowel Dis"},{"key":"1228_CR29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.9738\/INTSURG-D-13-00038.1","volume":"99","author":"YR Su","year":"2014","unstructured":"Su YR, Shih IL, Tai HC, Wei SC, Lin BR, Yu HJ, et al. Surgical Management in Enterovesical Fistula in Crohn disease at a single medical center. Int Surg. 2014;99:120\u20135.","journal-title":"Int Surg"},{"key":"1228_CR30","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10620-016-4395-8","volume":"62","author":"J Zou","year":"2017","unstructured":"Zou J, Ji DN, Cai JF, Guan JL, Bao ZJ. Long-term outcomes and predictors of sustained response in patients with intestinal Behcet\u2019s disease treated with infliximab. Digest Dis Sci. 2017;62:441\u20137.","journal-title":"Digest Dis Sci."},{"key":"1228_CR31","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/rheumatology\/kep126","volume":"48","author":"S Iwata","year":"2009","unstructured":"Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Suzuki K, et al. Effects of anti-TNF-\u03b1 antibody infliximab in refractory entero-Beh\u00e7et's disease. Rheumatology. 2009;48:1012\u20133.","journal-title":"Rheumatology."},{"key":"1228_CR32","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/ibd.20457","volume":"14","author":"M Naganuma","year":"2008","unstructured":"Naganuma M, Sakuraba A, Hisamatsu T, Ochiai H, Hasegawa H, Ogata H, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behcet\u2019s disease. Inflamm Bowel Dis. 2008;14:1259\u201364.","journal-title":"Inflamm Bowel Dis"},{"key":"1228_CR33","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s00535-013-0872-4","volume":"49","author":"T Hisamatsu","year":"2014","unstructured":"Hisamatsu T, Ueno F, Matsumoto T, Kobayashi K, Koganei K, Kunisaki R, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet\u2019s disease: indication of anti- TNF\u03b1 monoclonal antibodies. J Gastroenterol. 2014;49:156\u201362.","journal-title":"J Gastroenterol"},{"key":"1228_CR34","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/rheumatology\/34.9.825","volume":"34","author":"I Pande","year":"1995","unstructured":"Pande I, Uppal SS, Kailash S, Kumar A, Malaviya AN. Behcet\u2019s disease in India: a clinical, immunological, immunogenetic and outcome study. Rheumatology. 1995;34:825\u201330.","journal-title":"Rheumatology."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1228-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1228-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1228-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:30:09Z","timestamp":1606437009000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1228-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,28]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1228"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1228-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2019,11,28]]},"assertion":[{"value":"7 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was approved by the medical ethics committee of Huadong Hospital affiliated to Fudan University with the following reference numbers: 2016\u2009K044 and 2018\u2009K031.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients agreed to publish this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"274"}}